On February 5, 2026, IQVIA Holdings Inc. (NYSE:IQV), a prominent player in clinical research services and healthcare intelligence, released its financial results for the fourth quarter and full year of 2025. The report highlights the company’s robust growth against a backdrop of industry challenges, showcasing its strategic initiatives and operational discipline.

Fourth-Quarter Performance Highlights

For the fourth quarter ending December 31, 2025, IQVIA reported revenues of $4.364 billion, marking a 10.3% increase on a reported basis and an 8.1% rise at constant currency compared to the same period in 2024. Key segments contributed to this growth:

Technology & Analytics Solutions (TAS): Revenue reached $1.821 billion, growing 9.8% on a reported basis and 7.1% at constant currency.

Research & Development Solutions (R&DS): Revenue stood at $2.333 billion, reflecting a 9.9% increase on a reported basis and 8.2% at constant currency. Excluding pass-throughs, R&DS revenue grew by 4.9% year-over-year.

Contract Sales & Medical Solutions (CSMS): This segment saw significant growth, with revenue of $210 million, up 18.6% on a reported basis and 15.3% at constant currency.

The company’s R&DS contracted backlog reached $32.7 billion as of December 31, 2025, representing a year-over-year increase of 5.3%. IQVIA anticipates approximately $8.3 billion of this backlog to convert into revenue over the next twelve months.

Strong Profit Margins

IQVIA's fourth-quarter financials also indicated a healthy profit margin:

GAAP Net Income: Increased to $514 million, a 17.6% rise year-over-year.

GAAP Diluted Earnings per Share (EPS): Reached $2.99, up 23.6% year-over-year.

Adjusted Net Income: Reported at $588 million, a 4.3% increase year-over-year.

Adjusted Diluted EPS: Rose to $3.42, marking a 9.6% increase year-over-year.

Adjusted EBITDA: Increased to $1.046 billion, up 5.0% year-over-year.

Full-Year 2025 Financial Overview

For the entire year of 2025, IQVIA achieved revenues of $16.310 billion, a 5.9% increase on a reported basis (4.8% at constant currency) compared to 2024. Detailed revenue contributions include:

TAS: $6.626 billion, a 7.6% increase on a reported basis.

R&DS: $8.896 billion, a 4.3% increase on a reported basis.

CSMS: $788 million, reflecting a 9.7% increase on a reported basis.

The full-year GAAP Net Income was $1.360 billion, down slightly by 0.9%, while GAAP Diluted EPS increased to $7.84, up 4.7% year-over-year. Adjusted Net Income for the year was $2.068 billion, up 1.3%, with Adjusted Diluted EPS at $11.92, a 7.1% rise year-over-year. Adjusted EBITDA for 2025 was $3.788 billion, up 2.8% year-over-year.

Financial Position and Share Repurchase

As of December 31, 2025, IQVIA's cash and cash equivalents were $1.980 billion, with total debt standing at $15.724 billion. This resulted in a net debt of $13.744 billion and a Net Leverage Ratio of 3.63x trailing twelve-month Adjusted EBITDA. The company's free cash flow for the fourth quarter was $561 million, contributing to a full-year free cash flow of $2.051 billion, which represented 99% of Adjusted Net Income.

In a move to enhance shareholder value, IQVIA repurchased $212 million of its common stock during the fourth quarter, culminating in full-year share repurchases of $1.244 billion. As of December 31, 2025, the company had $1.769 billion remaining under its share repurchase authorization.

Outlook for 2026

Looking ahead, IQVIA has issued guidance for 2026, projecting revenues between $17.150 billion and $17.350 billion. This forecast accounts for an anticipated contribution of about 150 basis points from acquisitions and a foreign exchange tailwind of approximately 100 basis points. Additionally, the company expects Adjusted EBITDA between $3.975 billion and $4.025 billion, with Adjusted Diluted EPS anticipated to range between $12.55 and $12.85.

Segment Reporting Changes

Effective January 1, 2026, IQVIA will implement changes in its segment reporting structure. The CSMS segment will be integrated into the TAS segment, which will be rebranded as Commercial Solutions. Furthermore, select Real-World offerings will transition from TAS to R&DS. This restructuring aligns with industry trends and aims to enhance operational efficiency, with minimal impact on segment revenue growth rates.

Conclusion

IQVIA’s strong financial performance in 2025 reflects its adaptability and strategic focus within a competitive landscape. As the company sets its sights on 2026, its robust backlog and operational efficiency position it well for continued growth in the evolving healthcare and life sciences sectors.

Original press release